Molecular Basis For G(2) Arrest Induced By 2 '-C-Cyano-21-Deoxy-1-Beta-D-Arabino-Pentofuranosylcytosine And Consequences Of Checkpoint Abrogation

Xiaojun Liu,Ying Guo,Yexiong Li,Yingjun Jiang,Sherri Chubb,Atsushi Azuma,Peng Huang,Akira Matsuda,Walter N. Hittelman,William K. Plunkett
DOI: https://doi.org/10.1158/0008-5472.CAN-05-0288
IF: 11.2
2005-01-01
Cancer Research
Abstract:2 '-C-cyano-2 '-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) is a nucleoside analogue with a novel mechanism of action that is currently being evaluated in clinical trials. Incorporation of CNDAC triphosphate into DNA and extension during replication leads to single-strand breaks directly caused by beta-elimination. These breaks, or the lesions that arise from further processing, cause cells to arrest in G(2). The purpose of this investigation was to define the molecular basis for G(2) checkpoint activation and to delineate the sequelae of its abrogation. Cell lines derived from diverse human tissues underwent G(2) arrest after CNDAC treatment, suggesting a common mechanism of response to the damage created. CNDAC-induced G(2) arrest was instituted by activation of the Chk1-Cdc25C-Cdk1/cyclin B checkpoint pathway. Neither Chk2, p38, nor p53 was required for checkpoint activation. Inhibition of Chk1 kinase with 7-hydroxystaurosporine (UCN-01) abrogated the checkpoint pathway as indicated by dephosphorylation of checkpoint proteins and progression of cells through mitosis and into G(1). Cell death was first evident in hematologic cell lines after G, entry. As indicated by histone H2AX phosphorylation, DNA damage initiated by CNDAC incorporation was transformed into double-strand breaks when ML-1 cells arrested in G(2). Some breaks were manifested as chromosomal aberrations when the G(2) checkpoint of CNDAC-arrested cells was abrogated by UCN-01 but also in a minor population of cells that escaped to mitosis during treatment with CNDAC alone. These findings provide a mechanistic rationale for the design of new strategies, combining CNDAC with inhibitors of cell cycle checkpoint regulation in the therapy of hematologic malignancies.
What problem does this paper attempt to address?